

The Timi Marketplace is Now Live - Enabling Health and Genomics Data Ownership

Giving patients an avenue to control and monetization opportunities of their health and genomics data.

AUSTIN, TEXAS, UNITED STATES, May 20, 2020 /EINPresswire.com/ --

TimiHealth is leading the way towards consumer monetization of [genomics](#) and health [data](#) with a 70/30 split with the owners of the data. In this

emerging alternative business model, consumers will receive 70% of the compensation received when they opt in to share their data in the TimiHealth [blockchain](#) powered ecosystem. To learn more and take control of your health and genomics data visit: <https://timihealth.com>



[Timihealth.com](https://timihealth.com)

“

We know how truly valuable health & genomics data and believe that consumers who opt-in should receive their fair share of the financial windfall that comes from their data.”

Will Lowe

WHY IT MATTERS

As recently as May 15th, it was publicized that a leading direct to consumer DNA testing company was asking hospitals to help recruit patients with COVID-19 to join its genetic studies of the disease, according to STAT. Health and genomics data is extremely valuable when pooled together whether it's for combating a global pandemic or advancing clinical research.

FINDING A BALANCE

We understand the need to find and advance treatments

whether it's for COVID-19 or other global health crises. TimiHealth's blockchain powered ecosystem provides the technology infrastructure that allows individuals the ability to own, control and opt-in to monetization opportunities of their health and genomics data.

“We know how truly valuable health and genomics data is beyond combating COVID-19. We believe that consumers who choose to share or sell their data should receive a fair share of the financial windfall that comes from the medicines and therapies that are developed. TimiHealth is on a mission to empower consumers/patients by allowing them to first compile their data in the highly secure TimiHealth Blockchain, while also giving them the ability to sell or refuse to sell that

data to researchers. We fundamentally believe that whether its direct to consumer DNA testing companies or global pharmaceutical corporations, the rightful owners of the data should receive a fair share of the windfalls derived from their data." said TimiHealth's co-founder Will Lowe.

Will Lowe

Timihealth Group Inc

+1 281-607-7770

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/517490023>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2020 IPD Group, Inc. All Right Reserved.